Clinical Trial

HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a open-label study to evaluate the safety and efficacy of autologous T-cells transfected with messenger ribonucleic acid (mRNA) encoding Hepatitis-B virus (HBV) antigen specific T cell receptor (TCR) in combination with nucleos(t)ide analogues (NAs) in HBeAg-positive and negative chronic hepatitis B patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-14; most recent amendment 2025-07-14.
Trial Details
NCT Number NCT06885710
Lead Sponsor Changhai Hospital
Collaborators: Guangzhou Lion TCR Co Ltd
Conditions Chronic Hepatitis b
Enrollment 19 participants
Start Date 2024-12-31
Primary Completion 2027-12-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-17